Cholestyramine + Cholestyramine + Tang
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Healthy
Conditions
Healthy
Trial Timeline
Jan 1, 2010 → Apr 1, 2010
NCT ID
NCT01062269About Cholestyramine + Cholestyramine + Tang
Cholestyramine + Cholestyramine + Tang is a approved stage product being developed by Daiichi Sankyo for Healthy. The current trial status is completed. This product is registered under clinical trial identifier NCT01062269. Target conditions include Healthy.
What happened to similar drugs?
20 of 20 similar drugs in Healthy were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01062269 | Approved | Completed |
Competing Products
20 competing products in Healthy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD0837 | AstraZeneca | Phase 1 | 29 |
| Valsartan | Novartis | Phase 1 | 29 |
| CSL112 + Placebo | CSL | Phase 1 | 29 |
| UT-15C | United Therapeutics | Phase 1 | 26 |
| VNA-318 + Placebo | Biotrial | Phase 1 | 19 |
| Open-label TRV734 125 mg + TRV734 blinded + Oxycodone IR 10 mg + Placebo | Trevena | Phase 1 | 19 |
| TRV130 + Moxifloxacin + Placebo | Trevena | Phase 1 | 19 |
| Radiolabeled TRV130 | Trevena | Phase 1 | 19 |
| TRV130A + Dextrose in Water | Trevena | Phase 1 | 19 |
| TRV734 | Trevena | Phase 1 | 19 |
| ALT02 + EU-licensed Herceptin + US-licensed Herceptin | Alteogen | Phase 1 | 29 |
| ENZ215 + EU Sourced Prolia + US Sourced Prolia | Alkem Laboratories | Phase 1 | 29 |
| KPL-404 | Kiniksa Pharmaceuticals | Phase 1 | 23 |
| MORF-057 + Placebo for MORF-057 | Eli Lilly | Phase 1 | 29 |
| Propranolol + Pseudoephedrine | Eli Lilly | Pre-clinical | 26 |
| LY2157299 | Eli Lilly | Phase 1 | 29 |
| Lasmiditan + Placebo | Eli Lilly | Phase 1 | 29 |
| LY3015014 + Placebo | Eli Lilly | Phase 1 | 29 |
| LOXO-783 | Eli Lilly | Phase 1 | 29 |
| LY2541546 - IV + LY2541546 - SC + Placebo | Eli Lilly | Phase 1 | 29 |